In addition to potential impacts on costs, the implementation of national pharmacare might enable the adoption of measures to encourage cheaper prescription patterns. Below nationwide pharmacare (both scenarios), wholesale drug costs (i.e., before shelling out charges and pharmacy mark-ups) are set to the national common prices. Spending on model name medicine previously lined by public plans retains the 20 per cent rebate.
A 25 per cent overall rebate is assumed for public plan spending on new brand identify medicine projected to enter the market over the projection horizon. Underneath the established order scenario, the DSM assumes a 20 per cent general rebate on current public plan spending on brand title medication. At the moment, the pan-Canadian Pharmaceutical Alliance negotiates with drug manufacturers on behalf of public plans to acquire confidential rebates on prescription drugs.